Antibody Drugs Market - Forecast(2022 - 2027)

Report Code: HCR 0153 Report Format: PDF + Excel

Antibody Drugs Market Overview

Antibody Drugs Market size is estimated to reach $148.3 billion by 2027, growing at a CAGR of 6.4% during the forecast period 2022-2027. Antibody indicates a class of protective immunoglobulin generated owing to the incitement of antigens like pathogenic bacteria and viruses and can fasten particularly to antigens. Antibody drugs which include antibody substances are made by antibody engineering technology on the basis of cell and gene engineering technology. Adcetris® is a CD30-directed Antibody Drug conjugate (ADC); meaning that it includes a targeted therapy monoclonal antibody and an antineoplastic (chemotherapy) agent. Adcetris® Is utilized for the treatment of mature grown-up patients with formerly untreated stage III or IV classical Hodgkin lymphoma (cHL) in integration with chemotherapy. Immunotherapy is a kind of cancer treatment that increases the natural defenses of the body to combat cancer. There are numerous kinds of immunotherapy including monoclonal antibodies and tumor-agnostic treatments like checkpoint inhibitors, oncolytic virus therapy, T-cell therapy, and cancer vaccines. Multidrug resistance in Escherichia coli has evolved into a concern that is increasingly noticed in humans but also in veterinary medicine globally. Escherichia coli is intrinsically vulnerable to almost all clinically appropriate antimicrobial agents. However, this bacterial species has a great capability to amass resistance genes, mostly by way of horizontal gene transfer.

The soaring application of protein-based therapies and medications termed monoclonal antibodies in the treatment of incessant ailments is set to drive the Antibody Drugs Market. The rise of targeted therapy and combinational therapy which may apply targeted therapy and immunotherapy are set to propel the growth of the Antibody Drugs Market during the forecast period 2022-2027. This represents the Antibody Drugs Industry Outlook.

Report Coverage

The report: Antibody Drugs Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Antibody Drugs Market.

By Drug Type: Monoclonal Antibodies, Antibody-Drug Conjugates, Polyclonal Antibodies.
By Application: Central Nervous System Ailments, Cancer, Autoimmune Ailments, Cardiovascular Disease, Others.
By Geography: North America (the U.S, Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, Russia and Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia, Rest of South America), and Rest Of The World (Middle East, Africa).

Key Takeaways

  • Geographically, North America Antibody Drugs Market accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the surging application of antibody drugs and immunotherapy in the North American region.
  • Antibody Drugs Market growth is being driven by the soaring accessibility of numerous antibody drugs developed as a result of progress in the field of biotechnology, the reduced side-effects associated with them, and the high efficiency in healing some ailments that were formerly regarded untreatable in conjunction with the surging application of monoclonal antibodies as part of immunotherapy. However, monoclonal antibodies are very high-priced owing to their heightened complexity and the soaring cost to manufacture them in comparison with other kinds of medications and this is one of the major factors hampering the growth of the Antibody Drugs Market. 
  • Antibody Drugs Market Detailed Analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Antibody Drugs Market report. 

Antibody Drugs Market: Market Share (%) by Region, 2021

For More Details on This Report - Request for Sample

Antibody Drugs Market Segment Analysis – By Product Type

The Antibody Drugs Market based on product type can be further segmented into Monoclonal Antibodies, Antibody-Drug Conjugates, and Polyclonal Antibodies. The Monoclonal Antibodies Segment held the largest market share in 2021. This growth is owing to the increasing application of monoclonal antibodies as immunotherapy in the treatment of ailments like cancer. Monoclonal antibodies serve as immunotherapy owing to their ability to make the immune system respond better to permit the body to detect and attack cancer cells more efficiently. The surging application of monoclonal antibody therapy for COVID-19 is further propelling the growth of the Monoclonal Antibodies segment.

Furthermore, the Antibody-Drug Conjugates segment is estimated to grow with the fastest CAGR of 6.9% during the forecast period 2022-2027 owing to the soaring application of antibody-drug conjugates as immunotherapy depending on the capability of monoclonal antibodies (mAbs) to aim at specific tumor-associated antigens (TAAs) and to be utilized as carriers to particularly transfer cytotoxic warheads into corresponding tumor cells.

Antibody Drugs Market Segment Analysis – By Application

The Antibody Drugs Market based on the application can be further segmented into Central Nervous System Ailments, Cancer, Autoimmune Ailments, Cardiovascular Disease, and Others. The Cancer Segment held the largest market share in 2021. This growth is owing to the increasing predominance of cancer worldwide resulting in the greater application of immunotherapy involving monoclonal antibodies. Monoclonal antibodies are a particular kind of antibody, developed in the laboratory to detect and destroy a specific target like cancer. The surging application of monoclonal antibodies for the treatment of colorectal cancer and their anticipated reduced side-effects are further propelling the growth of this segment.

Furthermore, the Cardiovascular Disease segment is estimated to grow with the fastest CAGR of 7.3% during the forecast period 2022-2027 owing to the surging application of antibody-based therapeutics including monoclonal antibodies against Proprotein convertase subtilisin/Kexin type 9 (PCSK9) (alirocumab, evolocumab) as immunotherapy treatment for the occurrence of cardiovascular disease.

Antibody Drugs Market Segment Analysis – By Geography

The Antibody Drugs Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America (Antibody Drugs Market) held the largest share with 36% of the overall market in 2021. The growth of this region is owing to the strong healthcare infrastructure in the region. The increasing essentiality of attending to the urgent unmet requirement in the treatment of cancer requiring the application of immunotherapy and immunological ailments like rheumatoid is further driving the growth of the Antibody Drugs Market in this region. The higher affordability of consumers and the soaring rate of acceptance of novel technology are further propelling the growth of the Antibody Drugs Market in the North American region.

Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like the increasing predominance of infectious ailments in countries like India and China in the Asia-Pacific region. The enormous patient base and the proliferating application of immunotherapy involving monoclonal antibodies in the treatment of cancer are further fuelling the progress of the Antibody Drugs Market in the Asia-Pacific region.

Antibody Drugs Market Drivers

Surging Applications Of Adcetris Are Projected To Drive The Growth Of Antibody Drugs Market:

ADCETRIS® (brentuximab vedotin) for injection is designated for the treatment of mature grown-up patients with formerly untreated Stage III/IV classical Hodgkin lymphoma (cHL) in integration with doxorubicin, vinblastine, and dacarbazine (AVD). ADCETRIS+AVD presented excellent efficacy vs ABVD, which is a chemotherapy regimen utilized in the first-line treatment of Hodgkin lymphoma. ADCETRIS® (brentuximab vedotin) for injection is designated for the treatment of mature grown-up patients with cHL at soaring hazard of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation. It is also designated for cases of relapsed cHL, formerly untreated sALCL or additional CD30-expressing PTCL, relapsed sALCL, and relapsed pcALCL or CD30-expressing MF.  The surging applications of Adcetris are therefore fuelling the growth of the Antibody Drugs Market during the forecast period 2022-2027.

Soaring Applications Of Immunotherapy Are Expected To Boost The Demand Of Antibody Drugs Market:

Targeted therapies are planned to attack cancer cells with the assistance of antibodies and chemotherapy. They are based on the concept that cancer cells have abnormal versions of some proteins, termed receptors, that are existing in normal cells but not in cancer cells. These targeted therapies can utilize antibodies against these receptors. Immunotherapy is a kind of treatment that utilizes the immune system to combat cancer. It is also termed biotherapy. This kind of treatment can be either utilized alone or in integration with additional therapies. Immunotherapy is a kind of biological therapy. Biological therapy is a kind of treatment that utilizes substances prepared from living organisms to treat cancer. Monoclonal antibodies, which are immune system proteins developed in the laboratory that are planned to fasten to particular targets on cancer cells. Certain monoclonal antibodies mark cancer cells so that they will be better observed and destroyed by the immune system. These kinds of monoclonal antibodies are a kind of immunotherapy. Monoclonal antibodies may also be termed therapeutic antibodies. The soaring applications of immunotherapy involving monoclonal antibodies are driving the growth of the Antibody Drugs Market during the forecast period 2022-2027.

Antibody Drugs Market Challenges

Functional Disadvantages Of Therapeutic Antibodies Are Hampering The Growth Of The Antibody Drugs Market:

Certain functional disadvantages of therapeutic antibodies have been noticed like insufficient pharmacokinetics and tissue accessibility and impaired interactions with the immune system and these deficiencies indicate areas where more research is required. Monoclonal antibodies after being initially developed, encountered severe issues when utilized as therapeutics. The first monoclonal antibodies were murine molecules and were identified as foreign when injected into patients, resulting in their removal by the patient's immune system. Moreover, in order to be efficient, antibodies are frequently required to interact with some elements of the immune system like receptors displayed on effector cells or the complement cascade. Owing to their murine nature, these early antibodies did not interact appropriately with constituents of the human immune system and their biological efficacy was seriously limited. These kinds of issues are thus hampering the growth of the Antibody Drugs Market.

Antibody Drugs Market - Landscape:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Antibody Drugs Market. Key companies of this market are:

  1. Abbott Laboratories
  2. GlaxoSmithKline plc
  3. Sanofi S.A.
  4. Novartis AG
  5. Eli Lilly & Company
  6. Femta Pharmaceuticals
  7. La Jolla Pharmaceuticals
  8. Spectrum Pharmaceuticals
  9. Alexion Pharmaceuticals
  10. Hoffman-La Roche

Recent Developments

  • In December 2021, Roche declared the introduction of the AVENIO Edge System, a core constituent of Roche’s strategy to progress sequencing technologies. Constructed on best-in-class foundational capabilities to transfer a completely-automatized, combined sequencing solution. The AVENIO Edge System is a pre-analytical platform for sequencing library preparation, target enrichment, and quantification steps that transfer combined, end-to-end regulation with trustworthy, constant high-quality results. 
  • In November 2021, Roche declared the introduction of the cobas® 5800 System, a novel molecular laboratory tool, in nations accepting the CE mark. Testing is one of the earliest lines of defense to safeguard a patient’s general well-being and is very important in expeditiously guiding their treatment. The cobas 5800 System assists in attending to challenges that the laboratories are encountering from a boost in inpatient testing, reimbursement complications, and the requirement for a more distinct testing menu while offering meaningful and timely outcomes.
  • In January 2021, Roche declared the CE-IVD introduction of its automatized digital pathology algorithms, uPath HER2 (4B5) image analysis, and uPath Dual ISH image analysis for breast cancer to assist in deciding the most excellent treatment strategy for every patient. The image analysis algorithms utilize artificial intelligence to back pathologists in making quicker, more precise patient diagnoses in breast cancer. A mutation in the HER2 gene, which happens in as many as 20 percent of the 2.1 million cases of breast cancer diagnosed worldwide every year, is accountable for intrusive development in certain patients.

Related Reports-

Antibody Testing Market – Forecast (2022 - 2027)

Report Code: HCR 1360

Protein Drugs Market – Forecast (2022 - 2027)

Report Code: HCR 0354

1. Antibody Drugs Market Overview
    1.1 Definitions and Scope
2. Antibody Drugs Market - Executive Summary
3. Antibody Drugs Market– Market Landscape
    3.1 Company Benchmarking- Key Companies
    3.2 Key Company Financial Analysis
    3.3 Market Share Analysis
    3.4 Patent Analysis
    3.5 Pricing Analysis (Comparison of General Price Offerings in the Market)
4. Antibody Drugs Market– Startup Company Scenario (Premium)
    4.1 Investment
    4.2 Revenue
    4.3 Venture Capital and Funding Scenario
5. Antibody Drugs Market– Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Scenario
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Antibody Drugs Market- Market Forces
    6.1 Market Drivers
    6.2 Market Constraints
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Antibody Drugs Market– By Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle Analysis
8. Antibody Drugs Market - By Drug Type (Market Size –$Million/$Billion) 
    8.1 Monoclonal Antibodies
    8.2 Antibody-Drug Conjugates
    8.3 Polyclonal Antibodies
9. Antibody Drugs Market – By Application (Market Size –$Million/$Billion) 
    9.1 Central Nervous System Ailments
    9.2 Cancer
    9.3 Autoimmune Ailments
    9.4 Cardiovascular Disease
    9.5 Others
10. Antibody Drugs Market- By Geography (Market Size -$Million/Billion)
    10.1 North America
        10.1.1 U.S
        10.1.2 Canada
        10.1.3 Mexico
    10.2 Europe
        10.2.1 Germany
        10.2.2 France
        10.2.3 UK
        10.2.4 Italy
        10.2.5 Spain
        10.2.6 Russia
        10.2.7 Rest of Europe
    10.3 Asia-Pacific
        10.3.1 China
        10.3.2 Japan
        10.3.3 South Korea
        10.3.4 India
        10.3.5 Australia & New Zealand
        10.3.6 Rest of Asia-Pacific
    10.4 South America
        10.4.1 Brazil
        10.4.2 Argentina
        10.4.3 Chile
        10.4.4 Colombia
        10.4.5 Rest of South America
    10.5 Rest Of The World
        10.5.1 Middle East
        10.5.2 Africa
11. Antibody Drugs Market- Market Entropy
    11.1 New product launches
    11.2 M&A's, collaborations, JVs, and partnerships
12. Antibody Drugs Market– Industry Competition Landscape (Premium)
    12.1 Market Share Analysis
        12.1.1 Global Market Share – Key Companies
        12.1.2 Market Share by Region – Key Companies
        12.1.3 Market Share by Countries – Key Companies
    12.2 Competition Matrix
    12.3 Best Practices for Companies
13. Antibody Drugs Market– Key Company List by Country Premium (Premium)
14. Antibody Drugs Market- Company Analysis
    14.1 Company 1
    14.2 Company 2
    14.3 Company 3
    14.4 Company 4
    14.5 Company 5
    14.6 Company 6
    14.7 Company 7
    14.8 Company 8
    14.9 Company 9
    14.10 Company 10
"*Financials would be provided on a best-efforts basis for private companies"
List of Tables

Table1: Antibody Drugs Market Overview 2021-2026
Table2: Antibody Drugs Market Leader Analysis 2018-2019 (US$)
Table3: Antibody Drugs Market Product Analysis 2018-2019 (US$)
Table4: Antibody Drugs Market End User Analysis 2018-2019 (US$)
Table5: Antibody Drugs Market Patent Analysis 2013-2018* (US$)
Table6: Antibody Drugs Market Financial Analysis 2018-2019 (US$)
Table7: Antibody Drugs Market Driver Analysis 2018-2019 (US$)
Table8: Antibody Drugs Market Challenges Analysis 2018-2019 (US$)
Table9: Antibody Drugs Market Constraint Analysis 2018-2019 (US$)
Table10: Antibody Drugs Market Supplier Bargaining Power Analysis 2018-2019 (US$)
Table11: Antibody Drugs Market Buyer Bargaining Power Analysis 2018-2019 (US$)
Table12: Antibody Drugs Market Threat of Substitutes Analysis 2018-2019 (US$)
Table13: Antibody Drugs Market Threat of New Entrants Analysis 2018-2019 (US$)
Table14: Antibody Drugs Market Degree of Competition Analysis 2018-2019 (US$)
Table15: Antibody Drugs Market Value Chain Analysis 2018-2019 (US$)
Table16: Antibody Drugs Market Pricing Analysis 2021-2026 (US$)
Table17: Antibody Drugs Market Opportunities Analysis 2021-2026 (US$)
Table18: Antibody Drugs Market Product Life Cycle Analysis 2021-2026 (US$)
Table19: Antibody Drugs Market Supplier Analysis 2018-2019 (US$)
Table20: Antibody Drugs Market Distributor Analysis 2018-2019 (US$)
Table21: Antibody Drugs Market Trend Analysis 2018-2019 (US$)
Table22: Antibody Drugs Market Size 2018 (US$)
Table23: Antibody Drugs Market Forecast Analysis 2021-2026 (US$)
Table24: Antibody Drugs Market Sales Forecast Analysis 2021-2026 (Units)
Table25: Antibody Drugs Market, Revenue & Volume,By Disease Cure, 2021-2026 ($)
Table26: Antibody Drugs Market By Disease Cure, Revenue & Volume,By Central nervous system ailment, 2021-2026 ($)
Table27: Antibody Drugs Market By Disease Cure, Revenue & Volume,By Allergic diseases, 2021-2026 ($)
Table28: Antibody Drugs Market By Disease Cure, Revenue & Volume,By Cancer, 2021-2026 ($)
Table29: Antibody Drugs Market By Disease Cure, Revenue & Volume,By Infections, 2021-2026 ($)
Table30: North America Antibody Drugs Market, Revenue & Volume,By Disease Cure, 2021-2026 ($)
Table31: South america Antibody Drugs Market, Revenue & Volume,By Disease Cure, 2021-2026 ($)
Table32: Europe Antibody Drugs Market, Revenue & Volume,By Disease Cure, 2021-2026 ($)
Table33: APAC Antibody Drugs Market, Revenue & Volume,By Disease Cure, 2021-2026 ($)
Table34: Middle East & Africa Antibody Drugs Market, Revenue & Volume,By Disease Cure, 2021-2026 ($)
Table35: Russia Antibody Drugs Market, Revenue & Volume,By Disease Cure, 2021-2026 ($)
Table36: Israel Antibody Drugs Market, Revenue & Volume,By Disease Cure, 2021-2026 ($)
Table37: Top Companies 2018 (US$)Antibody Drugs Market, Revenue & Volume
Table38: Product Launch 2018-2019Antibody Drugs Market, Revenue & Volume
Table39: Mergers & Acquistions 2018-2019Antibody Drugs Market, Revenue & Volume


List of Figures

Figure 1: Overview of Antibody Drugs Market 2021-2026
Figure 2: Market Share Analysis for Antibody Drugs Market 2018 (US$)
Figure 3: Product Comparison in Antibody Drugs Market 2018-2019 (US$)
Figure 4: End User Profile for Antibody Drugs Market 2018-2019 (US$)
Figure 5: Patent Application and Grant in Antibody Drugs Market 2013-2018* (US$)
Figure 6: Top 5 Companies Financial Analysis in Antibody Drugs Market 2018-2019 (US$)
Figure 7: Market Entry Strategy in Antibody Drugs Market 2018-2019
Figure 8: Ecosystem Analysis in Antibody Drugs Market 2018
Figure 9: Average Selling Price in Antibody Drugs Market 2021-2026
Figure 10: Top Opportunites in Antibody Drugs Market 2018-2019
Figure 11: Market Life Cycle Analysis in Antibody Drugs Market
Figure 12: GlobalBy Disease Cure Antibody Drugs Market Revenue, 2021-2026 ($)
Figure 13: Global Antibody Drugs Market - By Geography
Figure 14: Global Antibody Drugs Market Value & Volume, By Geography, 2021-2026 ($) 
Figure 15: Global Antibody Drugs Market CAGR, By Geography, 2021-2026 (%)
Figure 16: North America Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 17: US Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 18: US GDP and Population, 2018-2019 ($)
Figure 19: US GDP – Composition of 2018, By Sector of Origin
Figure 20: US Export and Import Value & Volume, 2018-2019 ($)
Figure 21: Canada Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 22: Canada GDP and Population, 2018-2019 ($)
Figure 23: Canada GDP – Composition of 2018, By Sector of Origin
Figure 24: Canada Export and Import Value & Volume, 2018-2019 ($)
Figure 25: Mexico Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 26: Mexico GDP and Population, 2018-2019 ($)
Figure 27: Mexico GDP – Composition of 2018, By Sector of Origin
Figure 28: Mexico Export and Import Value & Volume, 2018-2019 ($)
Figure 29: South America Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 30: Brazil Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 31: Brazil GDP and Population, 2018-2019 ($)
Figure 32: Brazil GDP – Composition of 2018, By Sector of Origin
Figure 33: Brazil Export and Import Value & Volume, 2018-2019 ($)
Figure 34: Venezuela Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 35: Venezuela GDP and Population, 2018-2019 ($)
Figure 36: Venezuela GDP – Composition of 2018, By Sector of Origin
Figure 37: Venezuela Export and Import Value & Volume, 2018-2019 ($)
Figure 38: Argentina Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 39: Argentina GDP and Population, 2018-2019 ($)
Figure 40: Argentina GDP – Composition of 2018, By Sector of Origin
Figure 41: Argentina Export and Import Value & Volume, 2018-2019 ($)
Figure 42: Ecuador Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 43: Ecuador GDP and Population, 2018-2019 ($)
Figure 44: Ecuador GDP – Composition of 2018, By Sector of Origin
Figure 45: Ecuador Export and Import Value & Volume, 2018-2019 ($)
Figure 46: Peru Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 47: Peru GDP and Population, 2018-2019 ($)
Figure 48: Peru GDP – Composition of 2018, By Sector of Origin
Figure 49: Peru Export and Import Value & Volume, 2018-2019 ($)
Figure 50: Colombia Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 51: Colombia GDP and Population, 2018-2019 ($)
Figure 52: Colombia GDP – Composition of 2018, By Sector of Origin
Figure 53: Colombia Export and Import Value & Volume, 2018-2019 ($)
Figure 54: Costa Rica Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 55: Costa Rica GDP and Population, 2018-2019 ($)
Figure 56: Costa Rica GDP – Composition of 2018, By Sector of Origin
Figure 57: Costa Rica Export and Import Value & Volume, 2018-2019 ($)
Figure 58: Europe Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 59: U.K Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 60: U.K GDP and Population, 2018-2019 ($)
Figure 61: U.K GDP – Composition of 2018, By Sector of Origin
Figure 62: U.K Export and Import Value & Volume, 2018-2019 ($)
Figure 63: Germany Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 64: Germany GDP and Population, 2018-2019 ($)
Figure 65: Germany GDP – Composition of 2018, By Sector of Origin
Figure 66: Germany Export and Import Value & Volume, 2018-2019 ($)
Figure 67: Italy Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 68: Italy GDP and Population, 2018-2019 ($)
Figure 69: Italy GDP – Composition of 2018, By Sector of Origin
Figure 70: Italy Export and Import Value & Volume, 2018-2019 ($)
Figure 71: France Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 72: France GDP and Population, 2018-2019 ($)
Figure 73: France GDP – Composition of 2018, By Sector of Origin
Figure 74: France Export and Import Value & Volume, 2018-2019 ($)
Figure 75: Netherlands Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 76: Netherlands GDP and Population, 2018-2019 ($)
Figure 77: Netherlands GDP – Composition of 2018, By Sector of Origin
Figure 78: Netherlands Export and Import Value & Volume, 2018-2019 ($)
Figure 79: Belgium Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 80: Belgium GDP and Population, 2018-2019 ($)
Figure 81: Belgium GDP – Composition of 2018, By Sector of Origin
Figure 82: Belgium Export and Import Value & Volume, 2018-2019 ($)
Figure 83: Spain Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 84: Spain GDP and Population, 2018-2019 ($)
Figure 85: Spain GDP – Composition of 2018, By Sector of Origin
Figure 86: Spain Export and Import Value & Volume, 2018-2019 ($)
Figure 87: Denmark Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 88: Denmark GDP and Population, 2018-2019 ($)
Figure 89: Denmark GDP – Composition of 2018, By Sector of Origin
Figure 90: Denmark Export and Import Value & Volume, 2018-2019 ($)
Figure 91: APAC Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 92: China Antibody Drugs Market Value & Volume, 2021-2026
Figure 93: China GDP and Population, 2018-2019 ($)
Figure 94: China GDP – Composition of 2018, By Sector of Origin
Figure 95: China Export and Import Value & Volume, 2018-2019 ($)Antibody Drugs Market China Export and Import Value & Volume, 2018-2019 ($)
Figure 96: Australia Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 97: Australia GDP and Population, 2018-2019 ($)
Figure 98: Australia GDP – Composition of 2018, By Sector of Origin
Figure 99: Australia Export and Import Value & Volume, 2018-2019 ($)
Figure 100: South Korea Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 101: South Korea GDP and Population, 2018-2019 ($)
Figure 102: South Korea GDP – Composition of 2018, By Sector of Origin
Figure 103: South Korea Export and Import Value & Volume, 2018-2019 ($)
Figure 104: India Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 105: India GDP and Population, 2018-2019 ($)
Figure 106: India GDP – Composition of 2018, By Sector of Origin
Figure 107: India Export and Import Value & Volume, 2018-2019 ($)
Figure 108: Taiwan Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 109: Taiwan GDP and Population, 2018-2019 ($)
Figure 110: Taiwan GDP – Composition of 2018, By Sector of Origin
Figure 111: Taiwan Export and Import Value & Volume, 2018-2019 ($)
Figure 112: Malaysia Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 113: Malaysia GDP and Population, 2018-2019 ($)
Figure 114: Malaysia GDP – Composition of 2018, By Sector of Origin
Figure 115: Malaysia Export and Import Value & Volume, 2018-2019 ($)
Figure 116: Hong Kong Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 117: Hong Kong GDP and Population, 2018-2019 ($)
Figure 118: Hong Kong GDP – Composition of 2018, By Sector of Origin
Figure 119: Hong Kong Export and Import Value & Volume, 2018-2019 ($)
Figure 120: Middle East & Africa Antibody Drugs Market Middle East & Africa 3D Printing Market Value & Volume, 2021-2026 ($)
Figure 121: Russia Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 122: Russia GDP and Population, 2018-2019 ($)
Figure 123: Russia GDP – Composition of 2018, By Sector of Origin
Figure 124: Russia Export and Import Value & Volume, 2018-2019 ($)
Figure 125: Israel Antibody Drugs Market Value & Volume, 2021-2026 ($)
Figure 126: Israel GDP and Population, 2018-2019 ($)
Figure 127: Israel GDP – Composition of 2018, By Sector of Origin
Figure 128: Israel Export and Import Value & Volume, 2018-2019 ($)
Figure 129: Entropy Share, By Strategies, 2018-2019* (%)Antibody Drugs Market
Figure 130: Developments, 2018-2019*Antibody Drugs Market
Figure 131: Company 1 Antibody Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 132: Company 1 Antibody Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 133: Company 1 Antibody Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 134: Company 2 Antibody Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 135: Company 2 Antibody Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 136: Company 2 Antibody Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 137: Company 3Antibody Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 138: Company 3Antibody Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 139: Company 3Antibody Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 140: Company 4 Antibody Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 141: Company 4 Antibody Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 142: Company 4 Antibody Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 143: Company 5 Antibody Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 144: Company 5 Antibody Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 145: Company 5 Antibody Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 146: Company 6 Antibody Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 147: Company 6 Antibody Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 148: Company 6 Antibody Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 149: Company 7 Antibody Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 150: Company 7 Antibody Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 151: Company 7 Antibody Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 152: Company 8 Antibody Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 153: Company 8 Antibody Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 154: Company 8 Antibody Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 155: Company 9 Antibody Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 156: Company 9 Antibody Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 157: Company 9 Antibody Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 158: Company 10 Antibody Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 159: Company 10 Antibody Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 160: Company 10 Antibody Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 161: Company 11 Antibody Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 162: Company 11 Antibody Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 163: Company 11 Antibody Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 164: Company 12 Antibody Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 165: Company 12 Antibody Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 166: Company 12 Antibody Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 167: Company 13Antibody Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 168: Company 13Antibody Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 169: Company 13Antibody Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 170: Company 14 Antibody Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 171: Company 14 Antibody Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 172: Company 14 Antibody Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 173: Company 15 Antibody Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 174: Company 15 Antibody Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 175: Company 15 Antibody Drugs Market Net Sales Share, By Geography, 2018 (%)